Radiopharm Theranostics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RADX research report →
Companywww.radiopharmtheranostics.com
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.
- CEO
- Riccardo Canevari
- IPO
- 2024
- Employees
- 14
- HQ
- Carlton, VIC, AU
Price Chart
Valuation
- Market Cap
- $5.90M
- P/E
- -1.66
- P/S
- 4.02
- P/B
- 1.44
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 172.70%
- Op Margin
- -402.78%
- Net Margin
- -363.95%
- ROE
- -93.08%
- ROIC
- -59.92%
Growth & Income
- Revenue
- $3.63M · 1114.27%
- Net Income
- $-38,342,457 · 20.04%
- EPS
- $-5.28 · 85.33%
- Op Income
- $-38,173,865
- FCF YoY
- -59.50%
Performance & Tape
- 52W High
- $16.25
- 52W Low
- $3.62
- 50D MA
- $4.52
- 200D MA
- $5.15
- Beta
- 0.78
- Avg Volume
- 162.74K
Get TickerSpark's AI analysis on RADX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 28 | Voliotis Dimitris | other | 7,657,334 |
| Mar 18, 26 | HOPPER PAUL | other | 0 |
| Mar 18, 26 | HOPPER PAUL | other | 0 |
| Mar 18, 26 | HOPPER PAUL | other | 0 |
| Jul 1, 28 | HOPPER PAUL | other | 6,048,542 |
| Sep 13, 24 | HOPPER PAUL | other | 27,500,000 |
| Jul 1, 25 | HOPPER PAUL | other | 1,403,723 |
| Nov 25, 22 | HOPPER PAUL | other | 3,571,428 |
| Mar 18, 26 | Laurita Aaron James | other | 0 |
| Nov 25, 22 | Laurita Aaron James | other | 17,857 |
Our RADX Coverage
We haven't published any research on RADX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RADX Report →